The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Rho GTPases modulate malignant transformation of tumor cells
Open accessAbstract
Rho GTPases are involved in the acquisition of all the hallmarks of cancer, which comprise 6 biological capabilities acquired during the development of human tumors. The hallmarks include proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis programs, as defined by Hanahan and Weinberg. (1) Controlling these hallmarks are genome instability and inflammation. Emerging hallmarks are reprogramming of energy metabolism and evading immune destruction. To give a different view to the readers, we will not be focusing on invasion, metastasis, or cytoskeletal remodeling, but we will review here how Rho GTPases contribute to other hallmarks of cancer with a special emphasis on malignant transformation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Tumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559
RHO GTPASES: Biochemistry and Biology
Jaffe, A. B., & Hall, A. (2005) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.21.020604.150721 · Cited by 3,009
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
Christofk, H. R., Vander Heiden, M. G., Harris, M. H., Ramanathan, A., Gerszten, R. E., Wei, R., Fleming, M. D., Schreiber, S. L., & Cantley, L. C. (2008) · Nature · doi:10.1038/nature06734 · Cited by 2,820
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
A landscape of driver mutations in melanoma
Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J.-P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.024 · Cited by 2,610 · cited 7×
“A mutation in a homologous residue in Rac2 has also been found in melanoma, along with a mutation in Cdc42.(27) Rac1 is a recurrent somatic missense mutation at codon 29 that results in substitution of a proline to a serine residue.”
BackgroundInfluentialThe STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278 · cited 1×
“However, in most malignancies, STAT proteins and particularly STAT3, are aberrantly activated (tyrosine phosphorylation).(189,190) Some of the tumor-intrinsic functions of activated STAT3 include: inhibition of differentiation, cancer stem cell expansion and/or survival (WNT5A, CD44, and jagged), proliferation (stimul…”
BackgroundCOSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278
Cellular senescence in cancer and aging.
Collado, M., Blasco, M. A., & Serrano, M. (2007) · Cell · doi:10.1016/j.cell.2007.07.003 · Cited by 1,708
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma
Krauthammer, M., Kong, Y., Ha, B. H., Evans, P., Bacchiocchi, A., McCusker, J. P., Cheng, E., Davis, M. J., Goh, G., Choi, M., et al. (2012) · Nature Genetics · doi:10.1038/ng.2359 · Cited by 1,191
Senescence in tumours: evidence from mice and humans
Collado, M., & Serrano, M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2772 · Cited by 1,124 · cited 1×
“Therefore, senescence has been proposed as a barrier that tumor cells need to evade in order to sustaining aberrant proliferation.(180) The characteristic morphologic changes that senescent cells undergo—flattening and enlarged cell shapes—hint toward a role of Rho GTPases in this cytoskeletal reorganization.”
BackgroundYeatman, T. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1366 · Cited by 1,113
Targeting Mitochondrial Glutaminase Activity Inhibits Oncogenic Transformation
Wang, J.-B., Erickson, J. W., Fuji, R., Ramachandran, S., Gao, P., Dinavahi, R., Wilson, K. F., Ambrosio, A. L. B., Dias, S. M. G., Dang, C. V., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.08.009 · Cited by 821
Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation
Khosravi-Far, R., Solski, P. A., Clark, G. J., Kinch, M. S., & Der, C. J. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.11.6443 · Cited by 683 · cited 1×
“Activated RhoA or Rac1 stably expressed in NIH-3T3 cells or constitutively active Cdc42 expressed in Rat-1 fibroblasts promote anchorage-independent growth and the formation of tumors in nude mice.(79,83,98) Nevertheless, the oncogenic potential of Rho GTPases is not comparable to the morphologic transformation induce…”
BackgroundA role for Rho in Ras transformation
Qiu, R. G., Chen, J., McCormick, F., & Symons, M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.25.11781 · Cited by 533
Tumour-associated mutant p53 drives the Warburg effect
Zhang, C., Liu, J., Liang, Y., Wu, R., Zhao, Y., Hong, X., Lin, M., Yu, H., Liu, L., Levine, A. J., et al. (2013) · Nature Communications · doi:10.1038/ncomms3935 · Cited by 434
ROCK and JAK1 Signaling Cooperate to Control Actomyosin Contractility in Tumor Cells and Stroma
Sanz-Moreno, V., Gaggioli, C., Yeo, M., Albrengues, J., Wallberg, F., Viros, A., Hooper, S., Mitter, R., Féral, C. C., Cook, M., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.018 · Cited by 409 · cited 1×
“Furthermore, JAK1/2 and Rho-ROCK signaling have been placed upstream and downstream of each other; therefore JAKs and ROCKs may mutually enhance each other in tumor cells to propagate pro-tumorigenic signals.(198,199) In addition, NF-kB is a transcription factor which functions as a master regulator of genes implicate…”
BackgroundSelf-citationCytokinesis: Welcome to the Rho zone
Piekny, A., Werner, M., & Glotzer, M. (2005) · Trends in Cell Biology · doi:10.1016/j.tcb.2005.10.006 · Cited by 365
Molecular basis for Rac2 regulation of phagocyte NADPH oxidase
Diebold, B. A., & Bokoch, G. M. (2001) · Nature Immunology · doi:10.1038/85259 · Cited by 318
Thomas, E. K., Cancelas, J. A., Chae, H.-D., Cox, A. D., Keller, P. J., Perrotti, D., Neviani, P., Druker, B. J., Setchell, K. D. R., Zheng, Y., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.10.015 · Cited by 147
Preudhomme, C., Roumier, C., Hildebrand, M. P., Dallery-Prudhomme, E., Lantoine, D., Laï, J. L., Daudignon, A., Adenis, C., Bauters, F., Fenaux, P., et al. (2000) · Oncogene · doi:10.1038/sj.onc.1203521 · Cited by 135 · cited 1×
“RhoH has been reported to be frequently rearranged in non-Hodgkin’s lymphomas and multiple myeloma, and the 50untranslated region of RhoH gene is mutated in diffuse large cell lymphomas.(36,37) These studies might just highlight the important advances that nextgeneration sequencing analysis will be able to provide in…”
BackgroundVascular RhoJ is an effective and selective target for tumor angiogenesis and vascular disruption
Kim, C., Yang, H., Fukushima, Y., Saw, P. E., Lee, J., Park, J.-S., Park, I., Jung, J., Kataoka, H., Lee, D., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2013.12.010 · Cited by 131
Rac2 GTPase deficiency depletes BCR-ABL+ leukemic stem cells and progenitors in vivo
Sengupta, A., Arnett, J., Dunn, S., Williams, D. A., & Cancelas, J. A. (2010) · Blood · doi:10.1182/blood-2009-10-247437 · Cited by 52
Pak and Rac GTPases promote oncogenic KIT–induced neoplasms
Martin, H., Mali, R. S., Ma, P., Chatterjee, A., Ramdas, B., Sims, E., Munugalavadla, V., Ghosh, J., Mattingly, R. R., Visconte, V., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67509 · Cited by 45
Cited by
Are cancer cells really softer than normal cells?
Alibert, C., Goud, B., & Manneville, J. (2017) · Biology of the Cell · doi:10.1111/boc.201600078 · Cited by 366
Rho GTPase signaling in cancer progression and dissemination
Crosas-Molist, E., Samain, R., Kohlhammer, L., Orgaz, J. L., George, S. L., Maiques, O., Barcelo, J., & Sanz-Moreno, V. (2022) · Physiological Reviews · doi:10.1152/physrev.00045.2020 · Cited by 272
Self-citationOrgaz, J. L., Crosas-Molist, E., Sadok, A., Perdrix-Rosell, A., Maiques, O., Rodriguez-Hernandez, I., Monger, J., Mele, S., Georgouli, M., Bridgeman, V., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.003 · Cited by 151
Self-citationTargeting Rac and Cdc42 GEFs in Metastatic Cancer
Maldonado, M. D. M., Medina, J. I., Velazquez, L., & Dharmawardhane, S. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00201 · Cited by 122
RhoA GTPase oxidation stimulates cell proliferation via nuclear factor-κB activation
Kim, J.-G., Kwon, H.-J., Wu, G., Park, Y., Lee, J.-Y., Kim, J., Kim, S.-C., Choe, M., Kang, S. G., Seo, G.-Y., et al. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.12.013 · Cited by 31
Metadata
- Authors
- Orgaz, J. L., Herraiz, C., & Sanz-Moreno, V.
- Venue
- Small GTPases
- Publisher
- Informa UK Limited
- Published
- 2014-10-02
- Volume
- 5
- Issue
- 4
- Pages
- e983867
- ISSN
- 2154-1248 (ISSN-L)
- 2154-1256
- OpenAlex
- W2051747485
- Cited by
- 177
- References
- 24
- FWCI
- 7.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.